Friday, July 10, 2026

pharma · Syphilis · Human Immunodeficiency Virus

MEDA Pharma GmbH

MEDA Pharma GmbH clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Bad Homburg, DE HQ
89 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Bad Homburg, DE
Employees
89
Programs
8
Drugs
28
Patents
0
Intelligence · Clinical Programs

MEDA Pharma GmbH projects

2 ClinicalTrials.gov programs sponsored by MEDA Pharma GmbH.

MEDA Pharma GmbH has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. BENZATHINE BENZYLPENICILLIN , LINEZOLID

    MEDA Pharma GmbH & Co. KG

    Syphilis

    approved small molecule active

    1 trial
  2. DORALI

    MEDA Pharma GmbH & Co. KG

    Human Immunodeficiency Virus

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does MEDA Pharma GmbH have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.